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Essentials  
 Acquired thrombotic thrombocytopenic purpura (aTTP) is linked with significant 
morbidity.  
 Caplacizumab’s effect on major thromboembolic (TE) events, exacerbations and 
death was studied. 
 Fewer caplacizumab-treated patients had a major TE event, an exacerbation, or died 
vs. placebo. 
 Caplacizumab has the potential to reduce the acute morbidity and mortality associated 
with aTTP. 
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Summary  
Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is a life-threatening 
autoimmune thrombotic microangiopathy. In spite of treatment with plasma exchange and 
immunosuppression, patients remain at risk for thrombotic complications, exacerbations and death. 
In the Phase II TITAN study, treatment with caplacizumab, an anti-vWF Nanobody®, was shown to 
reduce the time to confirmed platelet count normalization and exacerbations during treatment.  
Objective: The clinical benefit of caplacizumab was further investigated in a post-hoc analysis of the 
incidence of major thromboembolic events and exacerbations during the study drug treatment 
period and TTP-related death during the study.  
Methods: The Standardized MedDRA Query (SMQ) for ‘embolic and thrombotic events’ was run to 
investigate the occurrence of major thromboembolic events and exacerbations in the safety 
population of the TITAN study, which consisted of 72 patients of whom 35 received caplacizumab 
and 37 received placebo.  
Results: Four events (1 pulmonary embolism and 3 aTTP exacerbations) were reported in 4 patients 
in the caplacizumab group, while 20 such events were reported in 14 patients in the placebo group 
(2 acute myocardial infarctions, 1 ischemic and 1 hemorrhagic stroke, 1 pulmonary embolism, 1 
deep vein thrombosis, 1 venous thrombosis and 13 aTTP exacerbations). Two of the placebo-treated 
patients died from aTTP during the study.  
Conclusion: In total, 11.4% of caplacizumab-treated patients versus 43.2% of placebo-treated 
patients experienced one or more major thromboembolic event, an exacerbation or died. This 
analysis shows the potential for caplacizumab to reduce the risk of major thromboembolic 
morbidities and mortality associated with aTTP. 
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Introduction 
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening autoimmune blood 
clotting disorder, manifested by systemic microvascular thrombosis leading to profound 
thrombocytopenia, hemolytic anemia, and organ ischemia[1]. It is caused by inhibitory 
autoantibodies to the von Willebrand Factor (vWF)-cleaving protease, ADAMTS13[2]. Decreased 
ADAMTS13 activity leads to an accumulation of ultra-large (UL) vWF multimers which bind to 
platelets and induce formation of microthrombi, causing tissue ischemia and organ dysfunction, and 
may result in overt major thromboembolic complications such as stroke, myocardial infarction, and 
arterial and venous thrombosis[3, 4]. Episodes of aTTP are associated with an acute mortality of up to 
20%[5], with most deaths occurring within 30 days of diagnosis[6] (median of 9 days[3]). 
 
The current mainstay of aTTP treatment is plasma exchange (PE) in conjunction with 
immunosuppression (e.g., with glucocorticoids and/or rituximab)[7]. PE removes ULvWF and 
autoantibodies and replenishes ADAMTS13, while immunosuppression inhibits autoantibody 
formation. However, current treatment has a slow onset of action and does not immediately address 
the pathophysiological platelet aggregation that leads to the formation of microthrombi[8]. 
 
Caplacizumab, an anti-vWF Nanobody®, immediately blocks the interaction of ULvWF with platelets 
and, therefore, inhibits further formation and accumulation of microthrombi. The efficacy and safety 
of caplacizumab have been evaluated in the phase II TITAN study[9]. Seventy-five patients with a 
clinical diagnosis of aTTP were randomized. Although ADAMTS13 activity was not part of the 
eligibility criteria, 77% of patients had a baseline ADAMTS13 activity <10%, while 11% had 
ADAMTS13 activity levels of 10% or more, and baseline ADAMTS13 results were missing for the 
remaining 12%. The results of the study showed that treatment with caplacizumab, as compared to 
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placebo, resulted in 39% faster normalization of platelet counts[9]. This translated into a reduced 
need for PE treatment (7.7 days vs. 11.7 days for placebo). Treatment with caplacizumab was also 
associated with a higher complete remission rate (i.e., confirmed platelet count response and 
absence of exacerbation) (81% vs. 46% for placebo), fewer exacerbations during the treatment 
period (3 patients vs. 11 for placebo), and a reduction in the percentage of patients refractory to 
treatment (5.7% vs. 21.6%, or 0% vs. 10.8% for placebo, depending on the definition used for 
refractoriness[10]). Seven patients in the caplacizumab group experienced a relapse within ten days 
after stopping study drug. All had ADAMTS13 levels that remained below 10%, suggesting 
unresolved autoimmune activity. The main safety finding was increased mild bleeding, mainly 
mucocutaneous, without requirement for vWF/FVIII administration. 
 
Here we report the results of a post-hoc analysis of the TITAN study data which evaluated the impact 
of treatment with caplacizumab on the incidence of major thromboembolic events and 
exacerbations during the study drug treatment and aTTP-related mortality during the study. 
Methods  
The Phase II TITAN study was a randomized, single-blind, placebo-controlled, multicenter study in 
adults experiencing an acute episode of aTTP requiring treatment with PE[9]. The main inclusion 
criteria were a clinical diagnosis of aTTP requiring the initiation of plasma exchange and a platelet 
count of less 100,000 per cubic millimeter.  
Seventy-five patients were randomized in a 1:1 ratio to receive either 10 mg caplacizumab or 
placebo daily in addition to standard-of-care throughout the PE period and for 30 days after 
thereafter. The safety population (i.e., all patients who received at least one dose of study drug) 
consisted of 72 patients, of whom 35 received caplacizumab and 37 received placebo, and was used 
for this analysis.  
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Major thromboembolic events were retrieved from the study’s safety database (i.e., all adverse 
events as reported by the Investigators) using the Standardized MedDRA (Medical Dictionary for 
Regulatory Activities) Query (SMQ) for ‘embolic and thrombotic events’. This query contains pre-
determined sets of MedDRA preferred terms for ‘arterial’, ‘venous’, and ‘vessel type unspecified and 
mixed arterial and venous’ events (MedDRA version 19.1 was used). Medical review of the output 
resulted in exclusion of two reported treatment-emergent adverse events from the analysis. One 
event was reported as ‘thrombotic catheter’, but was an obstruction within the malfunctioning 
catheter itself and not a venous thrombosis. The second event was reported as ‘thrombocytopenia’, 
but was present at baseline. Transient ischemic attacks were not considered major thromboembolic 
events and were, therefore, also not included in this analysis. ‘Thrombotic thrombocytopenic 
purpura’ is a predefined term in the SMQ ‘thrombotic and embolic events’. aTTP exacerbations are 
captured in the SMQ output as they reflect acute worsening of the presenting episode. They are 
reported as ‘aTTP exacerbations’. TTP-related mortality during the study was evaluated based on 
adverse event reporting, with relatedness to aTTP as judged and reported by the investigator. The 
number of events and the number and percentage of patients having an event or who died were 
summarized by treatment group for the safety population. The event times of major 
thromboembolic events, TTP exacerbations and TTP-related death were presented graphically by 
treatment group.   
 
Results and Discussion 
After medical review of the events defined by the SMQ, a total of 8 major thromboembolic events 
were identified (Table 1). One major thromboembolic event was reported in 1 patient in the 
caplacizumab group: 1 pulmonary embolism. In the placebo group, 7 major thromboembolic events 
were reported in 6 patients: 2 acute myocardial infarctions in 2 patients (reported verbatim terms 
were ‘non S-T elevation myocardial infarction’ and ‘acute myocardial infarction’, respectively), 1 
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ischemic and 1 hemorrhagic stroke in 1 patient (reported as separate events within the same 
patient; both events had the same onset and end date), 1 pulmonary embolism, 1 deep vein 
thrombosis (reported verbatim term was ‘right lower extremities deep vein thrombosis’), and 1 
venous thrombosis (reported verbatim term was ‘gemellar muscular veins thrombosis’). The 
frequency of major thromboembolic events in the placebo group was consistent with that reported 
in the literature[3, 4].  
 
The output of the SMQ also reflects the aTTP exacerbations that were reported as serious adverse 
events during the study drug treatment period. In total, 3 aTTP exacerbations occurred in 3 
caplacizumab-treated patients versus 13 aTTP exacerbations in 11 placebo-treated patients (Table 
1). TTP exacerbations re-expose patients to the same acute thrombotic risks of the disease. In the 
French TTP Registry, death was reported in 14% of the patients with an exacerbation[11].  
 
Two patients died during the study, both in the placebo group (Table 1). One patient died from 
severe refractory TTP, after 22 days of intensified daily plasma exchange treatment and 
immunosuppressive treatment (i.e., cyclophosphamide and rituximab). The second patient died 
from a cerebral hemorrhage after 10 days of daily plasma exchange throughout which platelet 
counts were in the range of 30x109/L. These findings are consistent with published data which show 
that refractoriness to treatment is an indicator of a poor prognosis for survival in patients with 
aTTP[12-14]. Of note, caplacizumab has been shown to reduce the incidence of refractoriness to 
therapy[10]. 
The composite analysis of major thromboembolic events and aTTP exacerbations during the study 
drug treatment period and aTTP-related deaths during the study showed that 11.4% of 
caplacizumab-treated patients versus 43.2% of placebo-treated patients experienced one or more 
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thromboembolic events, an exacerbation or died, which represents a 74% reduction (Table 1). All 
reported events occurred in patients with a baseline ADAMTS13 activity <10%, except for 3 events in 
3 placebo-treated patients: 1 patient with a myocardial infarction (missing baseline ADAMTS13 
result), 1 patient with a fatal cerebral hemorrhage (baseline ADAMTS13 75%) and 1 patient with an 
exacerbation (baseline ADAMTS13 90%). Of note, if these patients were excluded from the analysis, 
the results would have still favored caplacizumab. 
 
The time-to-event analysis indicates that the majority of these events occurred within the first 30 
days of enrollment (Figure 1). Most of the major thromboembolic events occurred during the daily 
PE period, while by definition, aTTP exacerbations occurred after reaching an initial platelet 
response (range: within 7-30 days of enrollment). These data confirm that patients experiencing an 
aTTP episode are at greatest risk for these life-threatening complications during this acute period. 
 
Major thromboembolic events may contribute to long-term cognitive and physical deficits of 
patients experiencing an episode of aTTP[15-20]. The impact of treatment with caplacizumab on the 
frequency of major thromboembolic events and exacerbations in the phase II TITAN study was highly 
clinically meaningful. By reducing acute thromboembolic complications and exacerbations, 
treatment with caplacizumab may also improve longer term outcomes. A Phase III study with 
caplacizumab in patients with aTTP is ongoing (NCT02553317), which will prospectively evaluate 
these important clinical endpoints as a composite endpoint consisting of major thromboembolic 
events, exacerbations and aTTP-related death. In addition, patients who completed the Phase III 
study will be followed in a long term follow-up study (NCT02878603). 
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Tables 
Table 1. Treatment-emergent major thromboembolic events and aTTP exacerbations during the 
treatment period and overall aTTP-related mortality in the Safety Population of the Phase II TITAN 
study 
 
Caplacizumab 
(N=35) 
Placebo 
(N=37) 
 # Events 
# 
Patients 
% of 
Patients # Events 
# 
Patients 
% of 
Patients 
Major thromboembolic events  
(based on SMQ, by preferred term)  
      
Acute myocardial infarction
[1]
 0 0 0 2 2 5.4 
Pulmonary embolism  1 1 2.9 1 1 2.7 
Deep vein thrombosis
[2]
 0 0 0 1 1 2.7 
Venous thrombosis
[3]
 0 0 0 1 1 2.7 
Ischemic stroke
[4]
 0 0 0 1 1 2.7 
Hemorrhagic stroke
[4]
 0 0 0 1 1 2.7 
       
aTTP exacerbations 
(based on SMQ, by preferred term) 
      
Thrombotic thrombocytopenic purpura
[5]
 3
 
 3
 
 8.6 13 11 29.7 
       
aTTP-related mortality       
Deaths related to TTP 0 0 0 2 2 5.4 
       
TOTAL 4 4
 [6]
 11.4 22 16
 [6]
 43.2 
 
 [1]
 verbatim terms: one acute myocardial infarction was reported as ‘non S-T elevation myocardial infarction’, 
one as ‘acute myocardial infarction’ 
[2]
 verbatim term: ‘right lower extremities deep vein thrombosis’ 
[3]
 verbatim term: ‘gemellar muscular veins thrombosis’ 
[4]
 the ischemic and hemorrhagic stroke were reported as separate events within the same patient. Both 
events had the same onset and end date  
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[5] 
this preferred term consisted of recurrences of aTTP during the treatment period, defined and reported per 
protocol as exacerbations of TTP
 
[6]
 a patient may have experienced more than one event 
 
Figure legend 
Figure 1. Event times of major thromboembolic events, TTP exacerbations and TTP-related death by 
treatment group. Time is expressed as days from first dose of study drug. 
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